The estimated Net Worth of Richard A. Fair is at least $1.73 Million dollars as of 17 March 2020. Mr. Fair owns over 5,000 units of Bellicum Pharmaceuticals Inc stock worth over $374 and over the last 8 years he sold BLCM stock worth over $0. In addition, he makes $1,732,890 as President, Chief Executive Officer und Director at Bellicum Pharmaceuticals Inc.
Richard has made over 3 trades of the Bellicum Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of BLCM stock worth $20,000 on 17 March 2020.
The largest trade he's ever made was buying 40,000 units of Bellicum Pharmaceuticals Inc stock on 10 September 2019 worth over $50,000. On average, Richard trades about 4,063 units every 13 days since 2017. As of 17 March 2020 he still owns at least 5,000 units of Bellicum Pharmaceuticals Inc stock.
You can see the complete history of Mr. Fair stock trades at the bottom of the page.
Richard A. Fair serves as President, Chief Executive Officer, Director of the Company. Mr. Fair has served as our President and Chief Executive Officer and a member of our Board since January 2017. From January 2014 to January 2017, Mr. Fair served as Senior Vice President, Therapeutic Head Oncology Global Product Strategy at Genentech, Inc., a biotechnology company that in 2009 was acquired and became a subsidiary of Roche Holding AG. His responsibilities included leadership of lifecycle strategy and global commercialization of the organization’s late stage and commercial oncology and hematology portfolio. From April 2006 to January 2014, Mr. Fair held other positions at Genentech, including Vice President, Global Product Strategy Hematology & Signaling, from November 2012 through December 2013, and Vice President, Sales & Marketing, Oral Oncolytics, from May 2010 to November 2012. Prior to Genentech, Mr. Fair held positions at Johnson & Johnson, a public pharmaceutical and medical device company. Since October 2018, Mr. Fair has served as a member of the board of directors of Clovis Oncology, Inc., a public biotechnology company. Mr. Fair received his B.S. in computer science from the University of Michigan and his MBA, with a dual concentration in finance and management, from Columbia University. Our Board believes that Mr. Fair’s background in the biotechnology and pharmaceutical industry, and extensive commercial and senior management experience qualify him to serve on our Board.
As the President, Chief Executive Officer und Director of Bellicum Pharmaceuticals Inc, the total compensation of Richard Fair at Bellicum Pharmaceuticals Inc is $1,732,890. There are no executives at Bellicum Pharmaceuticals Inc getting paid more.
Richard Fair is 51, he's been the President, Chief Executive Officer und Director of Bellicum Pharmaceuticals Inc since 2018. There are 8 older and 7 younger executives at Bellicum Pharmaceuticals Inc. The oldest executive at Bellicum Pharmaceuticals Inc is Dr. Alan K. Smith Ph.D., 63, who is the Chief Scientific Officer.
Richard's mailing address filed with the SEC is C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, SUITE 1200, HOUSTON, TX, 77098.
Over the last 10 years, insiders at Bellicum Pharmaceuticals Inc have traded over $18,000,835 worth of Bellicum Pharmaceuticals Inc stock and bought 249,666 units worth $2,145,232 . The most active insiders traders include Bros. Advisors Lp Baker Bro..., Bros. Advisors Lpbaker Feli... und Jon P Stonehouse. On average, Bellicum Pharmaceuticals Inc executives and independent directors trade stock every 32 days with the average trade being worth of $2,494. The most recent stock trade was executed by James M Daly on 3 January 2023, trading 60,414 units of BLCM stock currently worth $4,516.
bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.
Bellicum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: